Introduction

Glioblastoma (GBM), the most common primary brain tumor in adults, is still a formidable disease with median survival of 14-16 months despite current standard of care involving surgical resection with adjuvant chemotherapy. In recent years, immunotherapy has become a new avenue for GBM treatment with the discovery that the microenvironment created by the presence of GBM suppresses the normal immune system function, thereby allowing cancers to evade cytotoxic mechanisms, and that reversal of the immunosuppression may limit progression of the tumor [3]. According to the Cancer Research Institute, there are currently at least 27 ongoing clinical trials in brain cancer immunotherapy, including cancer vaccines, checkpoint inhibitors, oncolytic virus therapies, adoptive immune cell therapy, adjuvant therapies as well as monoclonal antibodies [4]. Clinicaltrials.gov also lists 68 completed and ongoing glioblastoma clinical trials in various stages of recruitment and completion for a variety of vaccines and immunotherapy treatments.

GBM's evasion of the immune system is multi-faceted. The involvement of CD4+ and CD8+ lymphocytes in the pathogenesis of GBM has been studied in detail. In recent works, tumor-associated macrophages (TAMs) have also been found to be intimately associated with the microenvironment of gliomas, which promotes tumor progression [5]. In particular, M2-type macrophages, which support tumor growth through increasing immunosuppressive factors, such as TGF-β, block the activation of various immune cells and suppress including suppression of activated CD8+ T-cells, therefore preventing anti-tumor functions [5, 6, 7, 8]. Neutrophils and granulocytes also play a role in the tumor microenvironment that manipulates the immune response.

Investigation and development of immune based therapies targeting separate components of the immunosuppressive glioma microenvironment would be a useful addition to treatment options for halting the progression of GBM. We seek to provide a summary and update on recent advancements in GBM immunotherapy, namely of viral therapies, checkpoint inhibitors and vaccine formulations, with an additional lens on recent non-lymphocyte targets.
Immunosuppressive Tumor Microenvironment and the Development of Immunotherapy

Since the discovery of the immune system's role in neoplastic processes, immunotherapy is now poised at the cutting edge for cancer treatment [9]. From research demonstrating the significant clinical benefit of trastuzumab as immunotherapy for metastatic breast cancer, the FDA’s approval of sipuleucel-T [Provenge] for prostate cancer treatment in 2010 and of the anti-CTLA-4 monoclonal antibody ipilimumab for late-stage melanoma in 2011, the field of oncological immunotherapy has picked up rapid pace [10, 11]. With regards to malignant gliomas, a variety of immune modalities have been extensively studied and considered, including harnessing stimulatory cytokines, administering autotumor antibodies or serotherapy, and immunogenic vaccines [12].

Glioblastoma (GBM) in particular still carries a dismal prognosis despite the current standard of care including surgery, radiotherapy, and adjuvant temozolomide chemotherapy [13]. One of the biggest difficulties in managing GBM involves various factors contributing to its ability to evade the tumor-targeting immune responses. To begin with, the central nervous system is uniquely contributing to its ability to evade the tumor-targeting immune responses. The mechanism of antigen presentation of the body’s immune system response similar to the body's lymphocytic response to viral illnesses. Some of the first discoveries of the role of TAA and TSA came from studies of melanoma. Through utilizing cytotoxic T-lymphocyte clones against autologous melanoma, Knuth et al., were able to identify three unique antigens expressed on the tumor cells of melanoma which helped shine light on a potential mechanism of tumor's evasion of the immune system. The mechanism of antigen loss prevented recognition of tumor antigen and targeting by cytotoxic T cells. [17].

Melanoma also served as the model for the discovery of the first TAA, MAGE-1, in 1991 [18] as well as the ability to create cytolytic T-cell clones that could target the antigen. Other melanoma antigenic targets that have since been recognized as potential therapeutic targets include gp100 and MAGE-3 [19, 20].

In the specific context of glioma, TSA such as mutated EGFRVIII are potentially excellent candidates for immunotherapy because of their specificity and inherent immunogenicity due to their foreign nature. Antigenic vaccines serve to deliver antigens to allow native T-cells to be primed to recognize TSA and thereby generate an immune response to the tumor [21, 22]. One such vaccine RITUEGA (rindopepimut) enhances immune response against EGFRVIII for GBM management [23]. In numerous animal models, vaccination with rindopepimut elicited antibody production and targeted binding of EGFRVIII receptors [24]. Unfortunately, Celldex Therapeutics, which manufactures Rindopepimut, recently announced the failure of the vaccine to improve EGFRVIII-positive GBM patients’ overall survival compared to temozolomide administration and the control group in the Phase III ACT IV study, discontinued in March 2016 [25].

Clinical trials on three other TAAs—interleukin-13 receptor alpha 2, EphA2, have also been studied in the survival of pediatric patients with glioblastomas and brainstem gliomas [26]. Patients with GBM tumors that expressed any of the following TAA—gp100, MAGE-1, HER2, TRP-2, AIM-2, IL13Ra2, were enrolled in a study and given an autologous dendritic cell vaccine with the TAAs, resulting in improved survival times depending on the tumor and prolonged progression-free survival in patients with newly-diagnosed GBM [27]. Furthermore, Gliovac, a prototype vaccine comprising of both autologous GBM TAA and allogeneic GBM TAA, showed that Rindopepimut achieved median overall survival times ranging from 24.3-24.6 months in patients with EGFRVIII-expressing GBM. However, the Phase III ACT IV study demonstrated that the control arm performed better than anticipated with the comparison of median overall survival being 20.4 months (Rindopepimut) and 21.1 months (control).

Cell-Based Therapy and Vaccines

Given the key roles and interactions cytokines and tumor cells themselves play in sustaining the immunosuppressive tumor microenvironment in cancer states, a natural avenue for oncologic immunotherapy to turn towards was cell-based and cytokine-secreting tumor cell vaccines.

Historically, in the 1970s, Trouillas et al., showed that high-grade astrocytoma patients receiving both radiation therapy and an autologous tumor cell vaccine had prolonged survival compared to those who only received radiation [29]. It has been shown that cytokine activity leads to potent immune system activity against neoplasms. Iwadate et al., showed that introduction of IL-2 with cytokine gene therapy in the microenvironment of brain tumor led to upregulation of tumor-infiltrating CD4+ and CD8+ T-cells [30]. Dranoff et al., created a series of different viruses and vaccines targeting different molecules involved in tumorigenicity which showed that tumor cells containing granulocyte-macrophage colony-stimulating factor (GM-CSF) promoted immunity against tumor cells through recruitment of dendritic cells, which then actively phagocytose and present tumor cells as antigens to other effector immune cells [31]. Since then, GM-CSF vaccines have been studied in numerous clinical trials for different cancers, including renal cell carcinoma.
non-small-cell lung cancer, breast cancer, and pancreatic cancer [32, 33, 34, 35, 36]. Specifically in GBM, the combination of GM-CSF with IFN-gamma immunization improved survival in a glioblastoma murine model [37]. Another study showed that a combined vaccination of tumor cells transduced with GM-CSF and the T-cell co-stimulatory protein, B7-2, successfully suppressed tumor cell growth at distant sites [38]. A recent Phase I clinical trial on GBM also demonstrated that the combination of GM-CSF with a vaccine containing multiple TAAs resulted in progression-free survival of 74% of patients at 6 months and 31% at 9 months [39] Whether as stand-alone therapy or as a combination avenue, GM-CSF and other cell-based therapies could hold substantial promise for cancer and GBM management.

**Dendritic Cell Vaccines**

Central to the immune system response are antigen-presenting cells that interact with T-cells, which can then target tumor cells and perform effector functions. Dendritic cells (DC) are especially suited for antigen presentation as they congregate in areas of high antigen exposure and rapidly upregulate the necessary cytokines and signaling to contact naïve T-cells [40]. DC could also present tumor antigens, establishing these cells as promising potential targets of immunotherapy [41]. In addition, DC play a significant role in combating the immunosuppressive tumor microenvironment. When tumor cell lysates were hitched to DCs, there was a subsequent increase in phagocytosis and humoral immunity response as well as improved long-term survival in a glioma model [42]. DCS also elicit more tumor-infiltrating T-cells and anti-tumor activity in a GBM clinical trial [43].

DC-containing cancer vaccines have featured prominently in animal studies and human clinical trials since the first study on B-cell lymphoma in mice in 1996 [44]. Various cancers have been studied with DC vaccine treatment, including renal cell carcinoma, melanoma, and sarcomas [45, 46, 47]. The first FDA-approved immunotherapeutic was the anti-tumor vaccine, sipuleucel-T, which includes DCs in its formulation, and it has been shown to improve survival and patient outcomes in advanced prostate cancer [48, 49].

DC vaccination has been found to suppress glioma and GBM growth through a variety of mechanisms, leading to improved clinical outcomes for patients. DC vaccines in combination with anti-angiogenesis molecules suppressed both angiogenesis processes as well as activity of glioma stem-cell-like cells [50]. The addition of DC vaccination also elicited a shift from regulatory T-cells to effector T-cells and a strong anti-tumor response, thereby improving glioma-bearing mice's survival by 300% [51]. Chang et al., followed GBM patients who were administered autologous DC-tumor vaccinations, which resulted in tumor regression as well as enhanced tumor-infiltrating T-cell counts and prolonged median and long-term survival [52]. Recently, a clinical trial on recurrent GBM tumors demonstrated that the combination of temozolomide and a vaccine that contained DCs and autologous tumor cells resulted in prolonged progression-free survival in a number of the patients [53].

**Adaptive T cell and Chimeric Antigen Receptor Immunotherapy**

Adaptive T-cell therapy (ACT) involves isolating tumor-infiltrating lymphocytes, expanding them in vitro and then transferring the cells back to the patient. The infused adoptive cytotoxic T-cells will then commence eliminating neoplasms [54]. Everson et al. studied the effect of adaptive T-cells targeting NY-ESO-1 in a murine model for human glioblastoma and found that NY-ESO-1 promoted a glioma-specific anti-tumor response and conferred survival benefit [55].

The development of chimeric antigen receptors (CARs) made it more efficient to create adaptive T-cells specific for TAA. CARs are comprised of an extracellular portion that recognizes antigen and an intracellular portion that involves signaling domains, which leads to improved lymphocyte proliferation and anti-apoptotic molecule generation as well as enhanced resistance against the immunosuppressive tumor microenvironment with the addition of CD28 to the CAR [56, 57]. Chow et al., used CAR constructs to generate T-cells specifically against erythropoietin-producing hepatocellular carcinoma A1 [EphA2], which is overexpressed on surfaces of malignant glioma cells [58]. An alternative to CARs, adoptive T-cells with bispecific T-cell engager (BiTE), was successfully used in a leukemia mouse model to show that T-cells could be induced to recognize and perform significant antitumor activity against CD19+ cell lines, leading to complete cancer remission [92].

Adaptive T cell therapy and CARs have also been adapted for GBM management. In vitro and in vivo animal studies demonstrated strong anti-glioma activity and disease regression. In addition, the first clinical trial of intracranially-administered IL-13(E13Y)-zetakine CD8[+] CTL targeting IL13Ra2 for recurrent GBM demonstrated that 2/3 patients experienced temporary anti-glioma responses [59]. Current trials include an EGFRvIII-targeted CAR T-cell approach in recurrent GBM tumors at the University of Pennsylvania [93].

**Immune Checkpoint Receptor Inhibitors**

Immune checkpoint receptors are well-known entities within the field of cancer immunotherapy at this point. Checkpoint receptors promote immunosuppression through the orchestration of antigen-presenting cells and effector and helper cells [60]. In a normal physiologic state, checkpoint receptors are helpful in that they prevent auto-immunity. However, neoplasms could exploit immune checkpoint receptors to evade the immune response. PD-1, expressed on T-cells, interacts with its ligands PD-L1 and PD-L2 and contributes to both CD4+ and CD8+ T-cell exhaustion [61]. CTLA-4 has been shown to decrease T-cell activation by establishing a competing site to bind on antigen-presenting cells. Therefore, antibodies that serve as immune checkpoint inhibitors could prevent T-cell suppression and exhaustion and eliminate the tumor microenvironment's immune resistance [62].

Historically, the immune checkpoints PD-1 and CTLA-4 have been the most studied. Following successful trials in animals, the
first human clinical trial of anti-PD-1 in patients with a variety of solid neoplasms demonstrated that disease regression was possible with administration of anti-PD-1 monoclonal antibodies [MDX-1106] [63]. The administration of ipilimumab, an anti-CTLA-4 antibody, to metastatic melanoma and ovarian cancer patients who had already received dendritic cell vaccines that enhanced antigen presentation led to promising results as well [64]. Recent clinical trials on anti-PD-1 and anti-CTLA-4 have included those for lung cancer and metastatic melanoma [65, 66].

Immunotherapy centered on immune checkpoint receptors in combination with existing treatment strategies has been significant for GBM management. In murine models of GBM, the combination of anti-PD-1 and radiotherapy showed improved survival [67]. In a glioblastoma study, mice were treated with 4-1BB agonist antibodies, anti-CTLA-4 antibodies, and radiation therapy. The combination therapy resulted in increased survival times of at least 50% long-term disease-free survival as well as greater counts of tumor-infiltrating lymphocytes [68]. Novel immune checkpoint receptor inhibitors have also emerged, such as anti-TIM-3. Combined triple therapy with anti-TIM-3, anti-PD-1, and stereotactic radiosurgery resulted in 100% overall survival in a murine GBM model with concurrent increases in anti-tumor T-cell infiltration and immune response [69]. Another monoclonal antibody directed against GITR, a molecule expressed on regulatory T-cells and involved in co-stimulatory signaling, also significantly improved survival rates in a glioma murine model when it was administered in conjunction with stereotactic radiosurgery [94]. With the variety of immune checkpoint inhibitor targets expressed within GBM, there is much more to be investigated in future clinical trials of GBM immunotherapy management in particular.

Viral Therapies

Oncolytic virus immunotherapy is a recent and upcoming avenue to combat cancers through utilizing viruses that could specifically replicate within and destroy cancer cells in addition to carrying antitumor factors. Talimogene laherparepvec [T-VEC] just became the first oncolytic virus therapy to be FDA-approved in the United States and Europe [84]. T-VEC is based on the herpes simplex virus type-1 structure and incorporates GM-CSF for promotion of antitumor response. From an earlier phase II trial utilizing the GM-CSF-expressing oncolytic herpes virus, named Oncovex in the trial, the injection increased antitumor response and diminished immunosuppressive Tregs and myeloid-derived suppressive cells in melanoma lesions [85]. In a phase III trial for patients with advanced melanoma, T-VEC administration resulted in prolonged overall survival as well as improved duration of response compared to administration of solely GM-CSF [86]. T-VEC also led to regression of melanoma lesion size [87].

HSV-1 also figures significantly in research and clinical trials targeted towards glioblastoma. M032 is a synthetic HSV-1 oncolytic virus therapy that expresses IL-12, which itself has antitumor and antiangiogenic effects. Thus far, M032 has been deemed safe for use in animal models [88].

In addition, viral peptides also could serve as targets for immunotherapy. Cytomegalovirus (CMV) peptides have been identified as glioma-associated antigens [89]. Schuessler et al., utilized autologous T-cell therapy directed towards CMV antigens in glioblastoma, finding that 40% of patients receiving the therapy were progression-free during the follow-up period and that patient response was associated with the genetic expression profiles of the individual tumors [90]. There is also currently an ongoing clinical trial at Baylor College of Medicine for administration of T-cells targeting CMV antigens in GBM [91].

Non-Lymphocytic Cells and Their Potential for Future Immunotherapeutics

Macrophages serve a vital purpose in the immune system by presenting antigens to lymphocytes and phagocytosing debris in addition to regulating the immune and inflammatory response [3]. There are two broad categories of macrophages based on their surrounding environment—M1, which promotes inflammatory cytokines, and M2, which promotes anti-inflammatory signaling and immunosuppression and includes tumor-associated macrophages [TAM]. TAMs are associated with tumor and disease progression and poor clinical outcomes [70]. A proposed mechanism of the pro-tumor growth influence of M2-type macrophages in the tumor microenvironment has been the secretion of chemokine periostin by glioblastoma stem cells [GSC], which leads to the recruitment and maintenance of M2-type TAMs as well as other monocyte derivatives [71]. TAMs even promote cancer metastases by altering the tumor microenvironment through factors, such as tumor-derived transforming growth factor and macrophage migration inhibitor factor [MIF] [72]. In addition, macrophages could be duped by certain cancer cells that expressed CD47, a molecule that inhibited immune cells’ phagocytic activity [73]. Overall, presence of M2-type tumor-infiltrating macrophages is positively correlated with the WHO grade of glioma, thereby associated with tumor growth and poor prognosis [74]. On the other hand, it has been shown that M1-type macrophages may represent a better therapeutic outcome for glioma patients [74].

Macrophages could be harnessed in cancer immunotherapy to combat tumor cells. TAMs that expressed TNF receptors on their surfaces were heavily involved in promoting glioma growth. However, blockade of TNF led to glioma tumor cell elimination and apoptosis [75]. Immunotherapy and induction of IL-15 also can protectVa24-invariant NKT cells, which themselves have the property of inhibiting tumorigenesis by targeting TAMs [76].

Tumor-associated neutrophils contribute to cancer immunosuppression through dampening CD8+ T-cell activity and promoting tumorigenesis [72]. For example, in hepatocellular cancer, tumor-infiltrating neutrophils that expressed PD-L1 suppressed T-cell activity and proliferation [77]. Of note, the ratio of neutrophils to lymphocytes has been correlated with poor clinical outcomes with higher neutrophil counts in colorectal cancer and glioblastoma [78, 79]. GBM tumors contained a significantly greater count of infiltrating neutrophils than even other types of glioma tumors [80]. In addition, CXCR2 is a tumorigenic IL-8 receptor that promotes neutrophil migration in an inflammatory environment, and it has been demonstrated that a high level of CXCR2 expression within gliomas was associated with likelihood of recurrence. Furthermore, inhibiting CXCR2 activity lowered glioma cell migration and proliferation [81]. However, in another level of complexity in neutrophils’ role in the tumor microenvironment, Graf et al., showed that neutrophils played a key role in an IL-6-induced anti-glioma response, and
that mice that were neutropenic could not reject glioma tumors [82]. Another role neutrophils play in cancer immunotherapy is as an innovative vehicle for delivery of anti-tumor monoclonal antibodies. Nanoparticles programmed to hijack neutrophils recruited by tumor shuttle a monoclonal antibody targeting the gp75 antigen in melanoma, leading to tumor growth suppression and improved survival in a murine model [83]. New strategies employing neutrophils for GBM management are still ongoing, with manipulating CXCR2 and other similar receptors through immunotherapy.

Conclusion and Future Directions

Cancer treatment has made significant strides with the introduction and implementation of various immunotherapy modalities, including cell-based therapies, oncolytic virus therapies, immune checkpoint inhibitors, and development of non-lymphocyte-targeted therapeutics. This review gives a broad overview on both the rationale underlying and recent updates to immunotherapy for a variety of cancers with a focus on glioblastoma(GBM). GBM tumors generate a profoundly immunosuppressive tumor microenvironment that dampens effector T-cell response and upregulates inhibitory cytokines and signaling. To produce enhanced antitumor responses and prolong patient survival times, different immunotherapy strategies have been employed, from DC vaccines to novel oncolytic virus therapies. A trend in recent immunotherapy clinical trials for GBM and other cancers has been to investigate the efficacy and safety of combining therapies, such as immune checkpoint inhibitors in concurrence with radiotherapy or a DC vaccine containing autologous tumor cells in concurrence with temozolomide chemotherapy. Thus far, the clinical implications have been promising and have opened new routes for future research into different receptors and cells that could play pivotal roles in cancer immunotherapy for GBM.

References


OPEN ACCESS


[91]. CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients with GBM (HERT-GBM), ClinicalTrials.gov, 2016.


